Clinical trial

Ireland Natalizumab (TYSABRI) Observational Program

NCT01943526

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2011-11-30

PhaseN/A

Study timeline

Study start (actual)2011-11-30Date precision: day

Registry last updated2018-05-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing-Remitting Multiple Sclerosisverified · MONDO: relapsing-remitting multiple sclerosis

Interventions

natalizumabBIOLOGICAL

Sponsors & collaborators

Biogenlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01943526 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.